<DOC>
	<DOCNO>NCT00854568</DOCNO>
	<brief_summary>The aim study compare CHOP versus CEOP-induced cardiotoxicity patient aggressive B-cell lymphoma . The hypothesis epirubicin associate less cardiotoxicity without compromise efficacy .</brief_summary>
	<brief_title>Comparison Study Doxorubicin Versus Epirubicin-induced Cardiotoxicity Patients With DLBCL</brief_title>
	<detailed_description>The doxorucin-containing regimen ( CHOP ) epirubicin-containing regimen ( CEOP ) frequently use patient aggress B-cell lymphoma institution . According Cochrane meta-analysis , epirubicin less cardiotoxic doxorubicin mg per mg basis . However , compare 50mg/m2 doxorubicin CHOP , epirubicin usually use high dose ( 70mg/m2 ) treat non-Hodgkin 's lymphoma ( NHL ) . Because correlation cumulative dose risk cardiotoxicity , reasonable speculate CEOP ( 70mg/m2 ) less cardiotoxicity CHOP ( 50mg/m2 ) regimen administer similar cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>Previously untreated aggressive Bcell lymphoma Age range 1875 year old ECOG performance status 02 Life expectancy 3 month Adequate organ function Previous serious cardiac disease History malignancies except cure basal cell carcinoma skin carcinoma insitu uterine cervix Pregnant lactate woman Serious uncontrolled disease intercurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>B-cell lymphoma</keyword>
	<keyword>CHOP</keyword>
	<keyword>CEOP</keyword>
	<keyword>Cardiotoxicity</keyword>
</DOC>